Financials Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
5.03 USD +3.07% Intraday chart for Affimed N.V. -2.33% -19.52%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 186.3 467.6 597.6 173 84.56 71.75 - -
Enterprise Value (EV) 1 186.3 322 418.7 0.9368 84.56 71.75 71.75 71.75
P/E ratio -4.89 x -9.53 x -10.1 x -1.93 x -0.8 x -0.98 x -1.15 x -1.34 x
Yield - - - - - - - -
Capitalization / Revenue 8.71 x 16.5 x 14.8 x 4.18 x 10.2 x 13.3 x 14.8 x 3.57 x
EV / Revenue 8.71 x 16.5 x 14.8 x 4.18 x 10.2 x 13.3 x 14.8 x 3.57 x
EV / EBITDA - -13,913,938 x -9,532,389 x -2,030,435 x - - - -
EV / FCF - -23.6 x -6.73 x -1.64 x - -0.91 x -0.7 x -0.51 x
FCF Yield - -4.24% -14.9% -61% - -110% -142% -195%
Price to Book - 6.51 x - - - - - -
Nbr of stocks (in thousands) 7,624 9,812 12,310 14,934 14,934 15,227 - -
Reference price 2 24.44 47.65 48.55 11.59 5.663 4.712 4.712 4.712
Announcement Date 4/28/20 4/15/21 3/31/22 3/23/23 3/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 21.39 28.36 40.37 41.35 8.275 5.389 4.832 20.11
EBITDA - -33.6 -62.7 -85.22 - - - -
EBIT 1 -32.38 -34.72 -64.03 -88.12 -106.7 -89.14 -109.6 -135.7
Operating Margin -151.35% -122.42% -158.62% -213.09% -1,288.95% -1,654% -2,268.05% -674.47%
Earnings before Tax (EBT) 1 -32.36 -41.36 -57.52 -86 -105.9 -89.22 -104.1 -130.9
Net income 1 -32.36 -41.37 -57.52 -86 -105.9 -88.02 -99.42 -112.6
Net margin -151.3% -145.86% -142.5% -207.98% -1,280.22% -1,633.18% -2,057.55% -559.89%
EPS 2 -5.000 -5.000 -4.800 -6.000 -7.090 -4.811 -4.112 -3.511
Free Cash Flow 1 - -19.83 -88.79 -105.6 - -79 -102 -140
FCF margin - -69.93% -219.95% -255.24% - -1,465.86% -2,110.96% -696.02%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 4/28/20 4/15/21 3/31/22 3/23/23 3/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 8.662 10.34 8.006 7.301 14.89 11.16 4.51 1.39 1.962 0.413 1.256 1.116 1.096 1.136 -
EBITDA - -23.78 - -21.31 - - - - - - - - - - -
EBIT 1 -18.57 -24.18 -17.13 -21.66 -19.21 -30.11 -31.46 -29.44 -24.92 -20.84 -24.69 -24.29 -21.79 -21.66 -
Operating Margin -214.37% -233.86% -214.01% -296.7% -129.02% -269.89% -697.58% -2,118.13% -1,270.29% -5,044.79% -1,966.78% -2,177.06% -1,989.36% -1,907.6% -
Earnings before Tax (EBT) 1 -17.1 -23.09 -16.66 -19.41 -16.49 -33.44 -31.98 -29.4 -24.36 -20.2 -23.16 -23.15 -24.24 -23.45 -
Net income 1 -17.1 -23.09 -16.66 -19.41 -16.49 -33.44 -31.98 -29.4 -24.36 -20.2 -24.12 -23.86 -21.68 -21.09 -
Net margin -197.36% -223.33% -208.16% -265.84% -110.76% -299.7% -709.16% -2,114.75% -1,241.34% -4,892.25% -1,920.88% -2,139.07% -1,979.17% -1,857.29% -
EPS 2 -1.400 -1.900 -1.400 -1.300 -1.100 -2.200 -2.100 -2.000 -1.600 -6.520 -1.547 -1.282 -1.105 -1.068 -0.8150
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/10/21 3/31/22 6/1/22 8/11/22 11/15/22 3/23/23 5/23/23 8/10/23 11/14/23 3/28/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - 146 179 172 - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -19.8 -88.8 -106 - -79 -102 -140
ROE (net income / shareholders' equity) - -74.8% - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - 7.330 - - - - - -
Cash Flow per Share - -2.320 - - - - - -
Capex 1 - 0.43 2.2 0.66 3.73 1.5 1.5 2
Capex / Sales - 1.52% 5.44% 1.59% 45.06% 27.83% 31.04% 9.94%
Announcement Date 4/28/20 4/15/21 3/31/22 3/23/23 3/28/24 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.712 EUR
Average target price
20.83 EUR
Spread / Average Target
+342.11%
Consensus
  1. Stock Market
  2. Equities
  3. AFMD Stock
  4. Financials Affimed N.V.